Dr. Jianhua Chang: Precision Thoracic Medical Oncology & Rare Lung Cancer Mutations at CAMS Shenzhen Hospital

Professional Profile

Dr. Jianhua Chang is a distinguished medical oncologist, Chief Physician, and Director of the Department of Medical Oncology at Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Hospital (CAMS Shenzhen Hospital). Regarded as one of the preeminent leaders in thoracic oncology across Southern China, Dr. Chang specializes in genomic-driven targeted treatments, advanced immunotherapy protocols, and innovative clinical trials for complex thoracic malignancies.

Recognizing the substantial diagnostic and therapeutic hurdles encountered by patients with atypical genetic alterations, Dr. Chang founded Shenzhen’s first specialized Rare Lung Cancer Mutation Clinic. His multidisciplinary team integrates comprehensive next-generation sequencing (NGS), liquid biopsy monitoring, and international pipeline therapies to formulate highly personalized treatment roadmaps for refractory lung and esophageal cancers.

Key Clinical Specializations

• Rare & Complex Lung Cancer Oncogenic Drivers: Pioneer in targeted therapy regimens for non-small cell lung cancer (NSCLC) harboring uncommon mutations, including ROS1 rearrangements, MET exon 14 skipping alterations, RET fusions, BRAF V600E, HER2 insertions, and KRAS G12C/non-G12C mutations.
• Founder of Shenzhen Rare Lung Cancer Mutation Clinic: Establishing standardized clinical protocols for ultra-rare molecular subtypes, delivering rapid genetic cross-matching, targeted therapy sequencing, and access to breakthrough compassionate-use and investigational drugs.
• Esophageal Cancer Targeted & Immunotherapy Strategies: Advanced systemic management of esophageal squamous cell carcinoma (ESCC) and adenocarcinoma using immune checkpoint inhibitors (PD-1/PD-L1), anti-angiogenic combinations, and biomarker-selected targeted therapies.
• Overcoming Immunotherapy & Targeted Resistance: Longitudinal molecular surveillance to identify secondary resistance mechanisms (such as MET amplification or secondary kinase mutations), guiding precision switch strategies and multi-agent combinatorial treatments.

Academic Leadership & Landmark Research (2024–2025)

Dr. Jianhua Chang serves as Principal Investigator for multiple national and international multicenter clinical trials. His research has been prominently featured in leading global journals, including the Journal of Thoracic Oncology (JTO):

• Targeted Therapy for ROS1 and MET Alterations: Spearheading Phase II clinical evaluations published in the Journal of Thoracic Oncology (JTO) evaluating novel next-generation tyrosine kinase inhibitors (TKIs) in treatment-naive and pretreated NSCLC patients harboring ROS1 fusions and MET exon 14 mutations.
• Translational Biomarkers for Immunotherapy Resistance: Identifying novel genomic and immune-microenvironment signatures that predict early failure or durable response to checkpoint inhibitors in thoracic cancers, accelerating biomarker-guided salvage regimens.
• Expert Consensus Guidelines: Contributing to national clinical consensus guidelines on rare lung cancer driver mutations, standardized biomarker testing, and esophageal cancer immunotherapy management.

International Patient Coordination & Fast-Track Access

China Medical Concierge – Shanghai (CMCS) provides independent health management and medical concierge services connecting international and cross-regional patients with top clinical specialists in China. For patients seeking medical evaluation with Dr. Jianhua Chang, CMCS offers comprehensive support:

• Comprehensive genomic sequencing (NGS) and pathology second opinion review;
• Expedited outpatient appointments at CAMS Shenzhen Hospital and coordination for specialized rare mutation clinics;
• Screening for clinical trial eligibility (Phase I–III targeted/immunotherapy trials);
• Full medical interpretation, medical report translation, and continuous longitudinal follow-up support.